Purpose: Trastuzumab deruxtecan (T-DXd) has been available since April 2021 via the
Cancer Drugs Fund for patients with unresectable or metastatic HER2-positive breast cancer …

TPS1096 Background: HER2-targeted therapies have improved survival in patients (pts)
with HER2+ advanced/metastatic breast cancer (mBC) but challenges remain, including …

e13035 Background: T-DXd is a HER2 antibody–drug conjugate. It improves patient
outcomes and is FDA approved for the treatment of patients with Her-2 positive and Her-2 …

Abstract Background: Trastuzumab Deruxtecan (T-DXd) is an antibody-drug conjugate
originally approved for use in patients with HER2–positive metastatic breast cancer (MBC) …

This is a summary of the article discussing the results of the DESTINY-Breast01 study
originally published in the New England Journal of Medicine. The DESTINY-Breast01 study …

Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? -
Annals of Oncology Skip to Main Content Skip to Main Menu Advertisement Annals of Oncology …

Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …

T rastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based …

1077 Background: In the clinical trial setting, T-DXd improves survival for patients with
HER2+ and HER2-low metastatic breast cancer (MBC), and has also shown preliminary …

Background Substantial improvement in survival has been seen in HER2+ advanced breast
cancer (ABC) over the past years with the introduction and widespread use of multiple novel …